PFKFB3 and Alzheimer disease: The identification of PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3) as a primary therapeutic target highlights the role of glucose metabolic dysfunction in AD pathogenesis.